US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Cartesian Therapeutics

5.85

-0.2300-3.78%

Post-market: 5.850.00000.00%16:18 EDT

Volume:321.74K

Turnover:1.87M

Market Cap:155.08M

PE:-1.17

High:6.17

Open:6.08

Low:5.60

Close:6.08

52wk High:15.57

52wk Low:5.60

Shares:26.51M

Float Shares:9.79M

Volume Ratio:2.35

T/O Rate:3.29%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-5.0200

EPS(LYR):-4.4814

ROE:-7029.26%

ROA:-14.82%

PB:-1.23

PE(LYR):-1.31

Loading ...

Overview Company News Filings

Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress

Cartesian Therapeutics highlights recent progress, outlines 2026

FDA Accepts IND Application for Cartesian Therapeutics' Descartes-08 in Myositis

Cartesian Therapeutics Inc - Enrollment on Track in Phase 3 Aurora Trial for Descartes-08

THOMSON REUTERS

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Top Brass Makes Big Moves as Cartesian Therapeutics Executives Cash In on Shares

Chief Medical Officer Milos Miljkovic Reports Disposal of Cartesian Therapeutics Inc. Common Shares

Cartesian Therapeutics Grants Stock Options to New Employees

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Adrian Ion Bot

Cartesian Therapeutics Announces the Appointment of Adrian BOT to Board of Directors

THOMSON REUTERS

Press Release: Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

Independent Director of Cartesian Therapeutics Picks Up 168% More Stock

Simply Wall St.

Director Timothy C. Barabe Acquires Common Shares of Cartesian Therapeutics Inc

Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.

H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’

Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)

Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RNAC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNAC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","market":"US","secType":"STK","nameCN":"Cartesian Therapeutics","latestPrice":5.85,"timestamp":1774641600000,"preClose":6.08,"halted":0,"volume":321737,"hourTrading":{"tag":"盘后","latestPrice":5.85,"preClose":5.85,"latestTime":"16:18 EDT","volume":291,"amount":1702.29,"timestamp":1774642718691,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.03782894736842112,"floatShares":9792400,"shares":26509024,"eps":-5.02,"marketStatus":"Market Closed","change":-0.23,"latestTime":"03-27 16:00:00 EDT","open":6.08,"high":6.17,"low":5.6,"amount":1874746.7742,"amplitude":0.09375,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.02,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"listingDate":1466568000000,"exchange":"NASDAQ","adjPreClose":6.08,"postHourTrading":{"tag":"盘后","latestPrice":5.85,"preClose":5.85,"latestTime":"16:18 EDT","volume":291,"amount":1702.29,"timestamp":1774642718691,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.349165,"impliedVol":0.91,"impliedVolPercentile":0.6134},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","floatShares":9792400,"roa":"-14.82%","roe":"-7029.26%","lyrEps":-4.481379,"volumeRatio":2.349165,"shares":26509024,"dividePrice":0,"high":6.17,"amplitude":0.09375,"preClose":6.08,"low":5.6,"week52Low":5.6,"pbRate":"-1.23","psRate":"55.44","week52High":15.57,"institutionHeld":0,"latestPrice":5.85,"eps":-5.02,"divideRate":0,"volume":321737,"delay":0,"ttmEps":-5.02,"open":6.08,"prevYearClose":7.21,"prevWeekClose":6.51,"prevMonthClose":7.59,"prevQuarterClose":7.21,"fiveDayClose":6.51,"twentyDayClose":7.59,"sixtyDayClose":6.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNAC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-09","symbol":"RNAC","fiscalQuarterEnding":"2025/12","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1773028800000,"reportTimeType":"pre","actualEps":-1.38},{"market":"US","date":"2025-11-06","symbol":"RNAC","fiscalQuarterEnding":"2025/09","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-1.38},{"market":"US","date":"2025-08-07","symbol":"RNAC","fiscalQuarterEnding":"2025/06","expectedEps":-0.76,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":0.5},{"market":"US","date":"2025-05-08","symbol":"RNAC","fiscalQuarterEnding":"2025/03","expectedEps":-0.61,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-13","symbol":"RNAC","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"pre","actualEps":-2.4}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNAC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNAC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.4444,"hold":0.2222,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4444,"analysts":9,"updateTime":1752120000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNAC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNAC","date":"2026-03-27","current":-1.165339,"percent":0.921002,"low":-14.109752,"twenty":-6.943412,"median":-3.490344,"eighty":-1.689135,"high":-0.322359,"avg":-4.051487,"sd":2.97204,"marketCap":161174865},"quantilePoints":[{"date":"2024-02-09","current":-12.195228,"twenty":-12.293822,"median":-12.139657,"eighty":-11.530164,"marketCap":110159496},{"date":"2024-02-16","current":-13.543282,"twenty":-12.82193,"median":-12.371802,"eighty":-12.018117,"marketCap":122336468},{"date":"2024-02-23","current":-12.9069,"twenty":-13.170416,"median":-12.72226,"eighty":-12.169773,"marketCap":116588031},{"date":"2024-03-01","current":-13.113052,"twenty":-13.187625,"median":-12.9069,"eighty":-12.193077,"marketCap":118450201},{"date":"2024-03-08","current":-0.474472,"twenty":-13.096919,"median":-12.72226,"eighty":-12.104521,"marketCap":104246325},{"date":"2024-03-15","current":-0.394571,"twenty":-13.085087,"median":-12.369113,"eighty":-0.499332,"marketCap":86691095},{"date":"2024-03-22","current":-0.518772,"twenty":-13.077916,"median":-12.18985,"eighty":-0.473381,"marketCap":113979437},{"date":"2024-03-28","current":-0.486782,"twenty":-13.018401,"median":-12.095738,"eighty":-0.472836,"marketCap":106950867},{"date":"2024-04-05","current":-0.371573,"twenty":-12.924109,"median":-11.522994,"eighty":-0.462369,"marketCap":81638284},{"date":"2024-04-12","current":-1.459867,"twenty":-12.9069,"median":-1.226402,"eighty":-0.444134,"marketCap":320747357},{"date":"2024-04-19","current":-1.398365,"twenty":-12.846668,"median":-1.459867,"eighty":-0.462369,"marketCap":307234719},{"date":"2024-04-26","current":-1.691309,"twenty":-12.729072,"median":-1.487381,"eighty":-0.467868,"marketCap":371597548},{"date":"2024-05-03","current":-1.978779,"twenty":-12.63227,"median":-1.536745,"eighty":-0.471303,"marketCap":434757574},{"date":"2024-05-10","current":-1.526348,"twenty":-12.47667,"median":-1.594687,"eighty":-0.472836,"marketCap":389021718},{"date":"2024-05-17","current":-1.839158,"twenty":-12.299559,"median":-1.62026,"eighty":-0.47633,"marketCap":468748036},{"date":"2024-05-24","current":-1.777713,"twenty":-12.193077,"median":-1.671483,"eighty":-0.482182,"marketCap":453087509},{"date":"2024-05-31","current":-2.195259,"twenty":-12.18985,"median":-1.697348,"eighty":-0.489671,"marketCap":559507906},{"date":"2024-06-07","current":-2.422885,"twenty":-12.179811,"median":-1.717665,"eighty":-0.504164,"marketCap":617523039},{"date":"2024-06-14","current":-2.045138,"twenty":-12.139657,"median":-1.777713,"eighty":-0.515905,"marketCap":521246392},{"date":"2024-06-21","current":-1.598266,"twenty":-12.069386,"median":-1.728138,"eighty":-0.518199,"marketCap":407351653},{"date":"2024-06-28","current":-1.991374,"twenty":-11.947846,"median":-1.777713,"eighty":-0.520305,"marketCap":507543431},{"date":"2024-07-05","current":-1.23169,"twenty":-11.531957,"median":-1.728138,"eighty":-0.526438,"marketCap":313922113},{"date":"2024-07-12","current":-1.241477,"twenty":-11.522994,"median":-1.709478,"eighty":-0.530124,"marketCap":316416386},{"date":"2024-07-15","current":-1.240079,"twenty":-9.729226,"median":-1.703386,"eighty":-0.53751,"marketCap":316060062},{"date":"2024-08-02","current":-1.081399,"twenty":-7.935458,"median":-1.699966,"eighty":-0.544895,"marketCap":275617201},{"date":"2024-08-09","current":-1.198323,"twenty":-2.548847,"median":-1.676743,"eighty":-0.772791,"marketCap":275192581},{"date":"2024-08-16","current":-1.345437,"twenty":-2.529995,"median":-1.625846,"eighty":-1.101689,"marketCap":308976908},{"date":"2024-08-23","current":-1.244878,"twenty":-2.507232,"median":-1.598266,"eighty":-1.148418,"marketCap":285883824},{"date":"2024-08-30","current":-1.388267,"twenty":-2.46827,"median":-1.531547,"eighty":-1.172903,"marketCap":318812851},{"date":"2024-09-06","current":-1.307262,"twenty":-2.424002,"median":-1.519153,"eighty":-1.173531,"marketCap":300210089},{"date":"2024-09-13","current":-1.496275,"twenty":-2.390626,"median":-1.497092,"eighty":-1.177113,"marketCap":343616533},{"date":"2024-09-20","current":-1.540036,"twenty":-2.248325,"median":-1.497406,"eighty":-1.182548,"marketCap":353666301},{"date":"2024-09-27","current":-1.616387,"twenty":-2.173184,"median":-1.49772,"eighty":-1.183457,"marketCap":371199939},{"date":"2024-10-04","current":-2.374287,"twenty":-2.173184,"median":-1.519153,"eighty":-1.187433,"marketCap":545250240},{"date":"2024-10-11","current":-2.176603,"twenty":-2.352646,"median":-1.530726,"eighty":-1.193387,"marketCap":499852543},{"date":"2024-10-18","current":-2.257757,"twenty":-2.310612,"median":-1.544226,"eighty":-1.200277,"marketCap":518489492},{"date":"2024-10-25","current":-2.299664,"twenty":-2.339564,"median":-1.569114,"eighty":-1.208188,"marketCap":528113202},{"date":"2024-10-31","current":-2.199769,"twenty":-2.325678,"median":-1.616387,"eighty":-1.208566,"marketCap":505172538},{"date":"2024-11-08","current":-2.028231,"twenty":-2.320475,"median":-1.625846,"eighty":-1.217877,"marketCap":496569789},{"date":"2024-11-15","current":-1.766791,"twenty":-2.31186,"median":-1.676743,"eighty":-1.221601,"marketCap":432561563},{"date":"2024-11-22","current":-1.725268,"twenty":-2.307988,"median":-1.693927,"eighty":-1.221601,"marketCap":422395604},{"date":"2024-11-29","current":-1.954681,"twenty":-2.306323,"median":-1.709478,"eighty":-1.229672,"marketCap":478562529},{"date":"2024-12-06","current":-2.388593,"twenty":-2.306323,"median":-1.725268,"eighty":-1.23169,"marketCap":584796802},{"date":"2024-12-13","current":-2.088591,"twenty":-2.321516,"median":-1.757967,"eighty":-1.238401,"marketCap":511347747},{"date":"2024-12-20","current":-2.024787,"twenty":-2.313583,"median":-1.76875,"eighty":-1.241197,"marketCap":495726646},{"date":"2024-12-27","current":-2.088883,"twenty":-2.309537,"median":-1.777713,"eighty":-1.243092,"marketCap":511419083},{"date":"2025-01-03","current":-1.778913,"twenty":-2.307156,"median":-1.777862,"eighty":-1.244452,"marketCap":435529430},{"date":"2025-01-10","current":-1.777862,"twenty":-2.305849,"median":-1.777862,"eighty":-1.244878,"marketCap":435272177},{"date":"2025-01-17","current":-1.989062,"twenty":-2.304427,"median":-1.779554,"eighty":-1.246554,"marketCap":486980042},{"date":"2025-01-24","current":-2.040548,"twenty":-2.299664,"median":-1.784789,"eighty":-1.253258,"marketCap":499585442},{"date":"2025-01-31","current":-2.036345,"twenty":-2.283748,"median":-1.80308,"eighty":-1.272811,"marketCap":498556430},{"date":"2025-02-07","current":-1.976453,"twenty":-2.276485,"median":-1.8278,"eighty":-1.28026,"marketCap":483893005},{"date":"2025-02-14","current":-1.999569,"twenty":-2.273364,"median":-1.845442,"eighty":-1.299813,"marketCap":489552573},{"date":"2025-02-21","current":-2.060513,"twenty":-2.263946,"median":-1.859179,"eighty":-1.303538,"marketCap":504473250},{"date":"2025-02-28","current":-1.892393,"twenty":-2.258524,"median":-1.87682,"eighty":-1.306703,"marketCap":463312761},{"date":"2025-03-07","current":-1.875581,"twenty":-2.211367,"median":-1.875581,"eighty":-1.307262,"marketCap":459196712},{"date":"2025-03-14","current":-5.557927,"twenty":-2.211367,"median":-1.881886,"eighty":-1.317995,"marketCap":430316947},{"date":"2025-03-21","current":-5.33039,"twenty":-2.277938,"median":-1.88594,"eighty":-1.323353,"marketCap":412700118},{"date":"2025-03-28","current":-4.805047,"twenty":-2.306323,"median":-1.893969,"eighty":-1.325512,"marketCap":372025970},{"date":"2025-04-04","current":-4.129128,"twenty":-2.32984,"median":-1.905491,"eighty":-1.337057,"marketCap":319693626},{"date":"2025-04-11","current":-3.466594,"twenty":-2.375387,"median":-1.926854,"eighty":-1.34432,"marketCap":268397566},{"date":"2025-04-17","current":-3.536863,"twenty":-2.423443,"median":-1.931271,"eighty":-1.357169,"marketCap":273838057},{"date":"2025-04-25","current":-4.03209,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"marketCap":312180567},{"date":"2025-05-02","current":-4.105705,"twenty":-2.552358,"median":-1.945456,"eighty":-1.384171,"marketCap":317880129},{"date":"2025-05-09","current":-7.05935,"twenty":-3.360856,"median":-1.954681,"eighty":-1.385102,"marketCap":270443712},{"date":"2025-05-16","current":-7.066125,"twenty":-3.485332,"median":-1.967259,"eighty":-1.38715,"marketCap":270703255},{"date":"2025-05-23","current":-6.195562,"twenty":-3.649293,"median":-1.975402,"eighty":-1.394326,"marketCap":237351991},{"date":"2025-05-30","current":-6.774808,"twenty":-3.931706,"median":-1.977504,"eighty":-1.416672,"marketCap":259542910},{"date":"2025-06-06","current":-6.327671,"twenty":-4.025398,"median":-1.983808,"eighty":-1.446219,"marketCap":242413077},{"date":"2025-06-13","current":-6.937404,"twenty":-4.149205,"median":-1.989062,"eighty":-1.451731,"marketCap":265771939},{"date":"2025-06-20","current":-6.774808,"twenty":-4.316511,"median":-1.991374,"eighty":-1.456219,"marketCap":259542910},{"date":"2025-06-27","current":-7.76393,"twenty":-4.826462,"median":-1.999044,"eighty":-1.463428,"marketCap":297436174},{"date":"2025-07-03","current":-7.59456,"twenty":-4.979046,"median":-2.003247,"eighty":-1.47767,"marketCap":290947602},{"date":"2025-07-11","current":-9.173091,"twenty":-5.33039,"median":-2.020584,"eighty":-1.478169,"marketCap":351421100},{"date":"2025-07-18","current":-8.488835,"twenty":-5.941507,"median":-2.024838,"eighty":-1.490688,"marketCap":325207266},{"date":"2025-07-25","current":-9.118892,"twenty":-6.287022,"median":-2.028231,"eighty":-1.49255,"marketCap":349344756},{"date":"2025-08-01","current":-8.67853,"twenty":-6.612213,"median":-2.031821,"eighty":-1.496275,"marketCap":332474467},{"date":"2025-08-08","current":-7.544353,"twenty":-6.70706,"median":-2.036345,"eighty":-1.497092,"marketCap":273558227},{"date":"2025-08-15","current":-8.196452,"twenty":-6.774808,"median":-2.042843,"eighty":-1.49772,"marketCap":297203340},{"date":"2025-08-22","current":-7.859415,"twenty":-6.950953,"median":-2.051056,"eighty":-1.50093,"marketCap":284982380},{"date":"2025-08-29","current":-7.371787,"twenty":-7.039026,"median":-2.060422,"eighty":-1.518941,"marketCap":267300991},{"date":"2025-09-05","current":-7.170999,"twenty":-7.05935,"median":-2.070182,"eighty":-1.51928,"marketCap":260020420},{"date":"2025-09-12","current":-7.142315,"twenty":-7.086783,"median":-2.081446,"eighty":-1.524951,"marketCap":258980338},{"date":"2025-09-19","current":-7.3933,"twenty":-7.086783,"median":-2.084663,"eighty":-1.52985,"marketCap":268081053},{"date":"2025-09-26","current":-6.783765,"twenty":-7.148052,"median":-2.088591,"eighty":-1.535541,"marketCap":245979317},{"date":"2025-10-03","current":-7.414813,"twenty":-7.201117,"median":-2.095187,"eighty":-1.539378,"marketCap":268861114},{"date":"2025-10-10","current":-7.242709,"twenty":-7.224056,"median":-2.14643,"eighty":-1.54674,"marketCap":262620624},{"date":"2025-10-17","current":-6.755081,"twenty":-7.209722,"median":-2.173618,"eighty":-1.557355,"marketCap":244939235},{"date":"2025-10-24","current":-6.453899,"twenty":-7.201117,"median":-2.199769,"eighty":-1.567209,"marketCap":234018378},{"date":"2025-10-31","current":-5.81568,"twenty":-7.176736,"median":-2.267478,"eighty":-1.592436,"marketCap":210876560},{"date":"2025-11-07","current":-4.091695,"twenty":-7.170999,"median":-2.283748,"eighty":-1.612763,"marketCap":196315417},{"date":"2025-11-14","current":-3.918507,"twenty":-7.148052,"median":-2.305763,"eighty":-1.619485,"marketCap":188006071},{"date":"2025-11-21","current":-3.875149,"twenty":-7.086783,"median":-2.31186,"eighty":-1.622774,"marketCap":185925782},{"date":"2025-11-28","current":-4.059422,"twenty":-7.068835,"median":-2.325678,"eighty":-1.626335,"marketCap":194767008},{"date":"2025-12-05","current":-3.739654,"twenty":-7.06451,"median":-2.365337,"eighty":-1.65105,"marketCap":179424881},{"date":"2025-12-12","current":-4.579722,"twenty":-7.060984,"median":-2.379788,"eighty":-1.672535,"marketCap":219730470},{"date":"2025-12-19","current":-3.988965,"twenty":-7.05935,"median":-2.423583,"eighty":-1.677012,"marketCap":191386540},{"date":"2025-12-26","current":-3.663777,"twenty":-7.058115,"median":-2.483579,"eighty":-1.682838,"marketCap":175784376},{"date":"2026-01-02","current":-3.907668,"twenty":-7.055526,"median":-2.5116,"eighty":-1.692356,"marketCap":187485999},{"date":"2026-01-09","current":-4.400869,"twenty":-7.049866,"median":-2.540887,"eighty":-1.697913,"marketCap":211149280},{"date":"2026-01-16","current":-3.988965,"twenty":-7.038171,"median":-2.581927,"eighty":-1.705823,"marketCap":191386540},{"date":"2026-01-23","current":-4.1082,"twenty":-7.03475,"median":-3.265826,"eighty":-1.71557,"marketCap":197107333},{"date":"2026-01-30","current":-3.783013,"twenty":-7.03475,"median":-3.400258,"eighty":-1.717665,"marketCap":181505169},{"date":"2026-02-06","current":-3.403628,"twenty":-7.025476,"median":-3.463248,"eighty":-1.725268,"marketCap":163302645},{"date":"2026-02-13","current":-3.474085,"twenty":-7.020408,"median":-3.474085,"eighty":-1.728138,"marketCap":166683114},{"date":"2026-02-20","current":-3.674617,"twenty":-7.019042,"median":-3.506604,"eighty":-1.751586,"marketCap":176304448},{"date":"2026-02-27","current":-4.525524,"twenty":-6.997119,"median":-3.520153,"eighty":-1.758278,"marketCap":217130110},{"date":"2026-03-06","current":-3.728815,"twenty":-6.991626,"median":-3.536863,"eighty":-1.76513,"marketCap":178904809},{"date":"2026-03-13","current":-1.651957,"twenty":-6.985963,"median":-3.528282,"eighty":-1.753846,"marketCap":215253274},{"date":"2026-03-20","current":-1.33662,"twenty":-6.957673,"median":-3.51344,"eighty":-1.717246,"marketCap":174164287},{"date":"2026-03-27","current":-1.236933,"twenty":-6.943412,"median":-3.490344,"eighty":-1.689135,"marketCap":161174865}],"updateTime":1774699262568},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNAC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602379658","title":"Cartesian Therapeutics Outlines 2026 Outlook and Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2602379658","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602379658?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:28","pubTimestamp":1767965311,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics ( ($RNAC) ) has shared an update. On January 9, 2026, Cartesian Therapeutics reported recent progress and its 2026 outlook, ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-outlines-2026-outlook-and-trial-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cartesian-therapeutics-outlines-2026-outlook-and-trial-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","RNAC","BK4139","BK4097","LU2065732104.USD"],"gpt_icon":0},{"id":"2602376412","title":"Cartesian Therapeutics highlights recent progress, outlines 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376412","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376412?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:15","pubTimestamp":1767964520,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC) highlighted its recent progress and outlined its 2026 strategic priorities across its cell therapy pipeline targeting...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-highlights-recent-progress-outlines-2026-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-highlights-recent-progress-outlines-2026-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2602768053","title":"FDA Accepts IND Application for Cartesian Therapeutics' Descartes-08 in Myositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602768053","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602768053?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:04","pubTimestamp":1767963868,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics Inc. announced that the U.S. Food and Drug Administration  has accepted its investigational new drug  application for a planned Phase 2 clinical trial of Descartes-08 in myositis. The trial, expected to begin in the first half of 2026, will evaluate the safety and efficacy of Descartes-08 in patients with moderate to severe multi-refractory dermatomyositis and antisynthetase syndrome. This regulatory review enables Cartesian to proceed with a randomized, double-blind, placebo-controlled trial, with the possibility of a seamless transition to a pivotal study based on interim results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL7X67Tg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","SG9999014005.SGD","SG9999014013.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4588","RNAC","LU0314104364.USD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","BK4139","LU2095319765.USD"],"gpt_icon":0},{"id":"2602376804","title":"Cartesian Therapeutics Inc - Enrollment on Track in Phase 3 Aurora Trial for Descartes-08","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376804?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:04","pubTimestamp":1767963854,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA50XFZ9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2602376690","title":"Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376690","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376690?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:04","pubTimestamp":1767963840,"startTime":"0","endTime":"0","summary":"Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential oppor","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216066/0/en/Cartesian-Therapeutics-Highlights-Recent-Progress-and-Outlines-2026-Outlook.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","MG","BK4097","BK4006","LU2065732104.USD","CAR","BK4187","IE00B66KJ199.SGD","BK4123","RNAC","PRGS","BK4077","BK4022","BK4230","LU0963586101.USD","IE00B19Z4B17.USD","IE00B7SZL793.SGD","SLE","IND","BK4139","CRS","IE0031619046.USD"],"gpt_icon":0},{"id":"2602348588","title":"Top Brass Makes Big Moves as Cartesian Therapeutics Executives Cash In on Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602348588","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602348588?lang=en_us&edition=fundamental","pubTime":"2026-01-09 10:02","pubTimestamp":1767924174,"startTime":"0","endTime":"0","summary":"New insider activity at Cartesian Therapeutics ( ($RNAC) ) has taken place on January 8, 2026. Recent insider activity at Cartesian Therapeutics sh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-brass-makes-big-moves-as-cartesian-therapeutics-executives-cash-in-on-shares-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-brass-makes-big-moves-as-cartesian-therapeutics-executives-cash-in-on-shares-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2602318208","title":"Chief Medical Officer Milos Miljkovic Reports Disposal of Cartesian Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602318208","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602318208?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:20","pubTimestamp":1767907230,"startTime":"0","endTime":"0","summary":"Milos Miljkovic, Chief Medical Officer of Cartesian Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL4DWZ82:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Chief Medical Officer Milos Miljkovic Reports Disposal of Cartesian Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2601089469","title":"Cartesian Therapeutics Grants Stock Options to New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2601089469","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601089469?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:05","pubTimestamp":1767701109,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics, Inc. has granted stock options to two new employees, allowing them to purchase a total of 7,350 shares of the company's common stock at an exercise price of $6.76 per share. The options vest 25% after one year on January 2, 2027, with the remaining shares vesting in thirty-six equal monthly installments, becoming fully vested by January 2, 2030. The stock options have a ten-year term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on January 06, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL9dVL9g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","RNAC","LU2210149790.SGD","SG9999014005.SGD","LU2095319765.USD","BK4139","IE00BKPKM429.USD","NDAQ","SG9999014013.SGD","SG9999014021.USD","BK4585","LU0314104364.USD","BK4588","LU2210150020.SGD","IE00B64PRP62.GBP","BK4112","IE00B3QW5Z07.USD","SG9999014039.USD"],"gpt_icon":0},{"id":"2601389232","title":"Cartesian Therapeutics Announces New Employment Inducement Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2601389232","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601389232?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:05","pubTimestamp":1767701100,"startTime":"0","endTime":"0","summary":"FREDERICK, Md., Jan.  06, 2026  (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases,","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213478/0/en/Cartesian-Therapeutics-Announces-New-Employment-Inducement-Grants.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2592182561","title":"Cartesian Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Adrian Ion Bot","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182561","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182561?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:04","pubTimestamp":1766095447,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Adrian Ion Bot as the beneficial owner, who serves as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDL8wtky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Cartesian Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Adrian Ion Bot","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2592950181","title":"Cartesian Therapeutics Announces the Appointment of Adrian BOT to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592950181","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592950181?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:05","pubTimestamp":1766091900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nTUA5TRWFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2592181998","title":"Press Release: Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592181998","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592181998?lang=en_us&edition=fundamental","pubTime":"2025-12-19 05:05","pubTimestamp":1766091900,"startTime":"0","endTime":"0","summary":"FREDERICK, Md., Dec. 18, 2025  -- Cartesian Therapeutics, Inc.  , a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company's Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science and Technology Committee of the Board.\"Dr. Bot brings a unique perspective shaped by pioneering work in first-in-class CAR T cell therapies, including the recent historic acquisition of Capstan's novel in-vivo CAR T technology by Abbvie, as well as the development of next generation RNA-based precision medicines, \" said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. \"His dynamic expertise will be particularly valuable while we continue to advance our current pipeline and explore potential opportunities beyond ex-v","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2590590968","title":"Independent Director of Cartesian Therapeutics Picks Up 168% More Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2590590968","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590590968?lang=en_us&edition=fundamental","pubTime":"2025-12-11 18:29","pubTimestamp":1765448959,"startTime":"0","endTime":"0","summary":"Potential Cartesian Therapeutics, Inc. ( NASDAQ:RNAC ) shareholders may wish to note that the Independent Director...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rnac/cartesian-therapeutics/news/independent-director-of-cartesian-therapeutics-picks-up-168","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rnac/cartesian-therapeutics/news/independent-director-of-cartesian-therapeutics-picks-up-168","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2590659713","title":"Director Timothy C. Barabe Acquires Common Shares of Cartesian Therapeutics Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590659713","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590659713?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:07","pubTimestamp":1765228069,"startTime":"0","endTime":"0","summary":"Timothy C. Barabe, Director, reported the acquisition of common shares of Cartesian Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cartesian Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL73l7d2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Director Timothy C. Barabe Acquires Common Shares of Cartesian Therapeutics Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2585707128","title":"Strategic Pivot and Promising Clinical Data Justify Buy Rating for Cartesian Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2585707128","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585707128?lang=en_us&edition=fundamental","pubTime":"2025-11-22 03:15","pubTimestamp":1763752523,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Tyler Van Buren has maintained their bullish stance on RNAC stock, giving a Buy rating on November 19. Tyler Van Buren has given h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-pivot-and-promising-clinical-data-justify-buy-rating-for-cartesian-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-pivot-and-promising-clinical-data-justify-buy-rating-for-cartesian-therapeutics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2584229829","title":"Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis","url":"https://stock-news.laohu8.com/highlight/detail?id=2584229829","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584229829?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:41","pubTimestamp":1763574060,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Cartesian Therapeutics Inc ::*CARTESIAN THERAPEUTICS ANNOUNCES STRONG EFFICACY SIGNAL IN PHASE 2 TRIAL OF DESCARTES-08 IN PATIENTS WITH SLE AND EXPANSION OF CLINICAL DEVELOPMENT INT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2K1SXx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2584493019","title":"Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2584493019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584493019?lang=en_us&edition=fundamental","pubTime":"2025-11-19 20:48","pubTimestamp":1763556480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 19, 2025 07:48 ET (12:48 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2584126948","title":"H.C. Wainwright cuts Cartesian target, calls shares ‘mispriced’","url":"https://stock-news.laohu8.com/highlight/detail?id=2584126948","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584126948?lang=en_us&edition=fundamental","pubTime":"2025-11-19 19:15","pubTimestamp":1763550925,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Cartesian Therapeutics (RNAC) to $30 from $40 and keeps a Buy rating on the shares. The firm say...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-cuts-cartesian-target-calls-shares-mispriced-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/h-c-wainwright-cuts-cartesian-target-calls-shares-mispriced-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2584963286","title":"Analysts Offer Insights on Healthcare Companies: Cartesian Therapeutics (RNAC) and Galmed Pharmaceuticals (GLMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584963286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584963286?lang=en_us&edition=fundamental","pubTime":"2025-11-19 04:30","pubTimestamp":1763497819,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Cartesian Therapeutics (RNAC – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) w...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-and-galmed-pharmaceuticals-glmd-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-cartesian-therapeutics-rnac-and-galmed-pharmaceuticals-glmd-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4581","BK4588","BK4137","BK4585","HCSG","RNAC","BK4139","XLV","XBI","GLMD","LU0029874061.USD","LABU"],"gpt_icon":0},{"id":"2584262466","title":"Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA) and Cartesian Therapeutics (RNAC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584262466","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584262466?lang=en_us&edition=fundamental","pubTime":"2025-11-17 21:30","pubTimestamp":1763386222,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Athira Pharma (ATHA – Research Report) and Cartesian Therapeutics...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-athira-pharma-atha-and-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-athira-pharma-atha-and-cartesian-therapeutics-rnac-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4007","BK4137","RNAC","LU0128526141.USD","XBI","BK4585","HCSG","XLV","LU0029874061.USD","BK4581","LABU","ATHA"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":70,"code":"91000000","status":"200"}]}}